CirCe T-DM1 phase II trial: Assessing the relevance of HER2-amplified circulating tumor cells as a tool to select HER2-negative metastatic breast cancer for treatment with T-DM1

Category Primary study
JournalCancer Research
Year 2013
This article has no abstract
Epistemonikos ID: 71b0ea3a71764c1efb245e248acb394bb5a62dc2
First added on: Feb 06, 2025